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Abstract: Therapeutic deep eutectic systems (THEDES) have dramatically expanded their popularity
in the pharmaceutical field due to their ability to increase active pharmaceutical ingredients
(APIs) bioavailability. However, their biological performance has not yet been carefully scrutinized.
Herein, THEDES based on the binary mixture of perillyl alcohol (POH) and ibuprofen (IBU) were
prepared using different molar ratios. Our comprehensive strategy includes the characterization of
their thermal and structural behavior to identify the molar ratios that successfully form deep eutectic
systems. The in vitro solubility of the different systems prepared has demonstrated that, unlike other
reported examples, the presence of the terpene did not affect the solubility of the anti-inflammatory
agent in a physiological simulated media. The biological performance of the systems was studied in
terms of their antimicrobial activity against a wide panel of microorganisms. The examined THEDES
showed relevant antimicrobial activity against all tested microbial strains, with the exception of
P. aeruginosa. A synergistic effect from the combination of POH and IBU as a eutectic system was
verified. Furthermore, the cytotoxic profile of these eutectic systems towards colorectal cancer (CRC)
in vitro cell models was also evaluated. The results provide the indication that the cell viability
varies in a dose-dependent manner, with a selective THEDES action towards CRC cells. With tunable
bioactivities in a ratio-dependent manner, THEDES enhanced the antimicrobial and anticancer
properties, representing a possible alternative to conventional therapies. Therefore, this study
provides foreseeable indications about the utility of THEDES based on POH and IBU as strong
candidates for novel active pharmaceutical systems.
Keywords: therapeutic deep eutectic systems; green chemistry; antimicrobial properties; natural
molecules; active pharmaceutical ingredients; anticancer properties
1. Introduction
Since ancient times, compounds of natural origin have played an essential role in society,
either as inspiration for various novel active pharmaceutical ingredients (APIs) or as therapeutic
agents themselves [1,2]. Among their different sources, medicinal herbs and plants have proven to
be essential in the development of modern medicine. Currently, as a result of centuries of compiling
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information about these molecules, we now have a vast library of promising raw material, with a
broad spectrum of chemically diverse structures and bioactivities [1,3–5]. Considering the ongoing
pursue for sustainability and compliance with the green chemistry metrics, natural compounds have
experienced a revised interest not only in academia, but also in industry, revealing their essential
contribution to solving the challenges faced by modern medicine [3,6–8].
Over the years, with pharmacology refinement and the emergence of several efficient fractionation
and separation techniques, several plant-derived classes of compounds started earning attention from
the scientific community due to their remarkable biological properties [1,3,5,6,8,9]. Terpenes represent a
prime example of these compounds. They are a diverse class of organic compounds produced by several
plants and some particular insects, with interesting bioactivities [10–13]. Terpenes and terpenoids
(i.e., terpenes with some extent of chemical modifications) are constituents of the majority of essential
oils produced from plants and flowers. These compounds possess several uses in various fields, from
cosmetics and food to pharmaceutical and biotechnology industries. As pharmaceutical ingredients,
terpenes present several beneficial effects, namely, as antioxidant, anti-inflammatory, anti-carcinogenic
and antibacterial agents [13–16]. Limonene, a cyclic monoterpene, and the major component of the oil
produced from citrus fruits peels, is a good example of the versatility displayed by these compounds,
since it finds application in all the above-mentioned fields [17,18]. Limonene has been used as a
common dietary supplement, as a botanical insecticide, in tissue preparation for histology and as
a solvent for cleaning, among other applications [17,19–21]. Its bioactivity is also quite remarkable,
possessing both significant anti-carcinogenic and antimicrobial activity, which are mainly attributed
to its metabolites, such as perillic acid (PA) [22–26]. In this sense, it has been reported that limonene
works as a sort of pro-drug since the therapeutic effect of its metabolites has been shown to be far
greater [18,25,27]. Aside from PA, perillyl alcohol (POH) is another interesting limonene metabolite that
has shown tremendous therapeutic potential [28]. This naturally occurring terpene is produced as a
secondary metabolite in plants, via the mevalonate pathway, by hydroxylation of its precursor limonene.
POH possesses several enticing biological properties, such as significant antimicrobial potential against
a number of clinically relevant pathogenic organisms (e.g., Candida albicans, Fusobacterium nucleatum
and Porphyromonas gingivalis) [29–31]. However, while POH has shown antitumoral activity both
in vitro and in vivo, it has failed to produce satisfactory results in a human clinical trial setting [28,32,33].
In fact, one of the main problems of POH application has been the administration form, which is in
part a consequence of its poor water solubility and resulting poor bioavailability. Considering that
carcinogenesis is a phenomenon not only restricted to abnormal cell proliferation, and angiogenesis
and inflammation play an important role in tumor progression, it is expected that the combination of an
anticancer agent, such as POH, with a well-described, non-steroidal anti-inflammatory drug (NSAID)
might result in a eutectic entity with enhanced anticancer properties. In this context, ibuprofen is
an ideal candidate being one of the most widely applied NSAIDs in clinical practice with a known
association with tumor reduction. Furthermore, recent studies have highlighted the potential of deep
eutectic systems containing ibuprofen as an API for cancer treatment [34,35].
Firstly, reported by Abbot and coworkers in 2004, deep eutectic systems (DES) have emerged as a
competitive “green” alternative to organic solvents and ionic liquids (ILs) [36–38]. DES can be defined
as a mixture of two or more compounds that in a specific molar ratio present a significant reduction in
the system melting point in comparison with its individual compounds. This depression is majorly
attributed to the establishment of hydrogen-bond interactions between the compounds, although
electrostatic interactions and Van der Waals forces can also play an important role [38–41]. When one of
the system components is an API, it is hence called a therapeutic deep eutectic system (THEDES) [39,42,43].
Their potential goes way beyond being a mere solvent for chemical engineering processes. DES already
have extensive applications in the pharmaceutical and biomedical fields [36,38,41,44], being extremely
interesting as eutecticity has shown the ability to tune the solubility and permeation of several
compounds, including various APIs [35,39].
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Hence, the main goal of this study was the development of a THEDES combining POH
and ibuprofen (IBU), to improve their solubility and bioavailability, creating a new potential therapeutic
formulation displaying two main biological effects, namely, being anti-bacterial and anti-cancer
(Figure 1).
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2. Materials and Methods
THEDES preparation: THEDES were prepared by mixing (S)-(−)-POH (W266418, Sigma Aldrich,
St. Louis, MO, USA) and IBU (I4883, Sigma Aldrich, St. Louis, MO, USA) at different olar ratios.
The systems were mixed under constant stirring at 60 ◦C. After 30 min, a clear solutio was obtained,
and the THEDES were left to cool down at room temperature (RT).
Differential scanning calorimetry (DSC): Experiments were performed, for each formulation,
using a TA i strume t, the DSC Q100 model (TA instruments, New Castle, DE, USA), in an aluminum
pan. The program used consisted of an initial heating step from −20 ◦C to 100 ◦C (heating rate
5 ◦C min−1), followed by an isothermal step of 2 min prior to a final cooling step at 20 ◦C. Experime ts
were performed under a nitroge atmosphere (purge gas flux of ca. 50 mL min−1).
Nuclear magnetic resonance (NMR): NMR experiments were carried out with a 400 MHz Bruker
Advance II. Mestrenova 12.0 software (Mestrelab Research, Santiago, Spain) was used for spectral
processing. The THEDES and ra materials were dissolved (30 mg/mL) i dimethyl sulfoxide-d6
(DMSO-d6, 99.9 atom % D, LOT. STBH4385, Sigma Aldrich). All the experiments were performed
when the systems were in equilibrium and no further change in their pro erties was observed.
Solubility evaluatio : The sol bility assessment w s performed using the pure API and the
previously prepared THEDES. Briefly, an excess of IBU and THEDES were added to a phosphate-buffered
saline solution (PBS, Sigma Aldrich, St. Louis, MO, USA), in separate vials, at 37◦, and stirred for
72 h. Thereafter, the samples were filtered using a hydrophilic PTFE syringe filter with a 0.22 µm
pore size (Filter Lab, Barcelona, Spain). The etermination f IBU solubilit was performed by HPLC,
using a Thermo Scientific Finnigan Surveyor (Thermo Scientific, Waltham, MA, USA), equipped with
a quaternary pump, solvent de sser, auto sampler and column oven, coupled to a UV-VIS detector
(Accela, Thermos Scientific, USA). The column used w s a keysto e kromasil 5 µm particle size, por size
100 Å, L × I.D. 250 mm × 4.6 mm (Thermo Scientific, W ltham, MA, USA) and the column t mp ratur
was 3 ◦C. The chromatographic separation was performed using a obile phase co sisting f PBS
(pH 6.8): acetonitrile = 65:35, v/v. The injection volume was 10 µL with a flow rate of 0.7 mL/min,
f llowing the procedure described by Jahan et al. [45] with the abs rbance of the solutions measured
at 222 nm. A calibratio curve using the respective THEDES and the API as standards was prepared
f r qua tification.
Assessment of antimicrobial a tivity: The antimicrobial potential of THEDES was evaluated
against microorganisms of linic l rele ance, namely, Staphylococcus aureus (ATCC 25923), an S. aureus
methicillin-resistant train (MRSA) (ATCC 700698), an S. epidermis methicillin-resistant strain (MRSE)
Pharmaceutics 2020, 12, 1121 4 of 17
(ATCC 35984), Pseudomonas aeruginosa (ATCC 27853), Escherichia coli (ATCC 25922) and Candida albicans
(ATCC 90029). The assessment was carried out as described in a previous work via a two-step
methodology [43,46]. Briefly, the formulations are first subjected to a disk diffusion assay (DDA),
using loaded blank antibiotic discs (CT0998B, Oxford), followed by the Minimum Inhibitory
Concentration (MIC), Minimum Bactericidal Concentration (MBC) and Minimum Fungicidal
Concentration (MFC) determination for the formulations that show relevant activity in DDA.
For comparison purposes, the isolated compounds were included in both steps, as internal controls,
and suitable antibiotics were used as the positive controls for antibacterial activity. The effective
concentration range used for MIC/MBC/MFC determination was between 2500 and 156.25 µg/mL.
Experiments were always carried out in triplicate, using independent microbial cultures to account
for biological variance. It should be noted that only formulations that retained a liquid state at room
temperature were used to carry out these assays.
Assessment of cytotoxicity, antiproliferative effect and selectivity index determination: THEDES
were evaluated in terms of their cytotoxicity and antiproliferative effects. The cytotoxic effect, here working
as a preliminary safety indicator, was assessed using a continuous cell line culture of heterogeneous human
epithelial colorectal adenocarcinoma cells (Caco-2) (ACC 169, DSMZ, Braunschweig, Germany). [47].
Briefly, the cells were subcultured in RPMI medium (Corning, Corning, NY, USA), supplemented
with 10% heat-inactivated fetal bovine serum (FBS, Corning, USA) and a 1% penicillin–streptomycin
solution (PS, Corning, NY, USA). The cell culture was maintained in a humidified atmosphere
at 37 ◦C with 5% CO2. The cytotoxicity assay was performed in accordance with ISO/EN 10993
guidelines. Caco-2 cells were seeded into 96-well plates at a density of 2 × 104 cells/well and allowed to
grow for 7 days, with medium renewal every 48 h. At Day 7, cells were incubated with culture
media (control) and different THEDES concentrations diluted in culture medium. After 24 h,
cells were washed twice with PBS and the cell viability was assessed using a CellTiter 96®
AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA), containing an MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) viability
reagent. Briefly, 100 µL of the viability reagent was added at each well in a 1:10 dilution and incubated
for 3 h. The absorbance was measured at 490 nm using a microplate reader (VICTOR NivoTM,
PerkinElmer, Waltham, MA, USA) and cell viability was expressed in terms of percentage of living
cells relative to the control. Three independent experiments were performed in triplicate.
The antiproliferative effect towards cancer cells was assessed using a continuous cell culture
of human Caucasian colon adenocarcinoma (HT29) (ACC 299, DSMZ, Germany); these cells form a
well-differentiated colorectal adenocarcinoma (CRC), and thus have been accepted as a CRC cell model
in 2D and 3D in vitro cultures. The cells were subcultured as described above. Briefly, HT29 cells
were seeded at a density of 1 × 105 cells/well in 96-well culture plates. After 24 h, cells were incubated
with culture media (control) and with different THEDES concentrations diluted in culture medium.
Cell proliferation was measured after 24 h using the MTS viability reagent, as previously described.
Furthermore, THEDES selectivity indexes were calculated as a ratio between the half maximal effective
concentrations (EC50) from the cytotoxic and antiproliferative profiles previously obtained.
3. Results
3.1. Design and Characterization of THEDES
The design of THEDES is still a trial-and-error process due to the lack of knowledge on
the interactions established between the counterparts and, thereby, computational simulation programs.
Table 1 summarizes the visual aspects of the different formulations at RT, indicating that up to a molar
ratio of 2:1 pasty-like solids were obtained, whereas using a higher amount of POH (i.e., molar ratio 3:1)
led to a transparent liquid with a few crystal particles on the bottom of the vials. Using molar ratios
of 4:1; 6:1 and 8:1, no crystals were detected, and a completely transparent liquid was successfully
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obtained. The liquid phase is a strong indication of lack of lattice arrangement and intermolecular
interactions between the counterparts, as elsewhere reported [39,42,48].
Table 1. Summary of the different POH:IBU therapeutic deep eutectic systems (THEDES) prepared in
this study.








The THEDES and IBU powder were analyzed by DSC up to 100 ◦C (Figure 2) in order to evaluate
the thermal events and confirm the results obtained by simply naked-eye observation. Compared with
the IBU (≈77.7 ◦C) thermogram, a shift of the melting point in THEDES was observed, which indicates a
gradual depression on the melting point of IBU as the mole fraction of POH increases. The thermograms
of THEDES up to a molar ratio of 3:1 present an endothermic peak, ranging from ≈62.2 ◦C to ≈38.3 ◦C,
which is far lower than the melting point of IBU.
Ph rmaceutics 2020, 12 5 of 17 
 
Table 1. Summary of the different POH:IBU therapeutic deep eutectic systems (THEDES) prepared 
in this st dy. 
Molar Ratio Visual Aspect at RT Melting Point (°C) 
1:1 Solid ≈57.9 
1:2 Solid ≈62.2 
2:1 i  ≈57.9 
3:1 Liquid with a few crystals ≈38.3 
4:1 Liquid - 
6:1 Liquid - 
8:1 iq i  - 
The THEDES and IBU powder were analyzed by DSC up to 100 °C (Figure 2) in order to evaluate 
the thermal events and confirm the results obtained by simply naked-eye observation. Compared 
with the IBU (≈77.7 °C) thermogram, a shift of the melting point in THEDES was observed, which 
indicates a gradual depression on the melting point of IBU as the mole fraction of POH increases. The 
thermograms of THEDES up to a molar ratio of 3:1 present an endothermic peak, ranging from ≈62.2 
°C to ≈38.3 °C, which is far lower than the melting point of IBU. 
 
Figure 2. DSC thermogram of IBU and POH:IBU at different molar ratios. 
Owing to the gap in understanding the interactions between the compounds, the 
supramolecular arrangement of THEDES were further evaluated using HNMR, allowing to study the 
intermolecular interactions of the atoms involved and even to confirm the ratios of the counterparts. 
The HNMR spectra for the isolated components and the molar ratios that remained in a liquid state 
at RT are presented in Figures 3 and 4, respectively. The remaining spectra are included in the 
Supplementary Materials (Figures S1–S4). 
There is a clear change in the peak correspondent to the POH hydroxyl group (δ = 4.59) (Figure 
3A) between the isolated compound and the compound while in THEDES form. Namely, the well-
defined triplet verified for the isolated compounds is presented, generally, when in THEDES form as 
a larger singlet (Figure 4), which is a hallmark of hydrogen-bond interactions. Likewise, it is possible 
to observe a suppression of the peak correspondent to IBU’s OH (δ = 12.21) (Figure 3B) when in 
THEDES form (Figure 4). These two facts heavily suggest the establishment of interactions between 
the two compounds, via hydrogen bonds, corroborating the results obtained by DSC analysis. 1H–
1H-nuclear Overhauser enhancement (NOESY) spectroscopy was also performed, with the results 
included as Supplementary Data (Figure S5). 
Figure 2. DSC thermogram of IBU and POH:IBU at different molar atios.
Owing to he gap in understanding he interactions between the compounds, the supramolecular
arrangement of THEDES w re further evaluated sing HNMR, allowing to study the i termolecular
interactions of the atoms involved and even to confirm the rati s of the counterparts. The HNMR
spectra for the isolated comp nents and the mol r ratios that remained in a liqui state at RT are
presented in Figures 3 and 4, respectively. The r maining sp ctra are clud d in th Supplementary
Materials (Figures S1–S4).
There is a clear change in the peak correspondent to the POH hydroxyl group (δ = 4.59) (Figure 3A)
between the isolated compound and the compound while in THEDES form. Namely, the well-defin d
triplet verified for the isolated compounds is presented, generally, when in THEDES form as a larger
singlet (Figur 4), which is a hallm rk of hydrogen-bond interactions. Likew s , it is po sible to
observe a suppression of the peak corresp ndent to IBU’s OH (δ = 12.21) (Figure 3B) when in THEDES
form (Figure 4). These two facts heavily suggest the establishment of interactions between the two
compounds, via hy rogen bonds, corroborating the results obtained by DSC analysis. 1H–1H-nuclear
Overhauser enhancem nt (NOESY) spectroscopy was al o erformed, with the results included as
Supplementary Data (Figu e S5).
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3.2. Solubility of Ibuprofen in Physiologically Simulated Media
In this work, we have evaluated the solubility of ibuprofen in the liquid samples prepared,
to understand how the effect of the increase in terpene ratio could be related to the solubility
enhancement of ibuprofen. The solubility evaluation was performed in POH:IBU molar ratios of
3:1, 4:1, 6:1 and 8:1, in comparison with IBU alone, but also POH and IBU in a physical mixture
(POH + IBU), where the two individual components are dissolved in PBS using the same concentration
as in the THEDES. In opposition to the previously reported results, an enhancement of IBU solubility
could not be identified when using this eutectic formulation (Figure 5).
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3.3. Antimicrobial Potential of the Formulated THEDES
To measure the antimicrobial effect of the developed THEDES, a two-step methodology was
applied. Firstly, a DDA was performed against a panel of microbial organisms relevant at the clinical
level. It should be noted that antimicrobial activity was only measured for the systems that were fully
liquid at RT, namely, a POH:IBU of 4:1, 6:1 and 8:1. The obtained results are presented in Table 2.
Table 2. Inhibition halo measurements (diameter (mm) ± SD) for the various THEDES formulations,
individual counterparts and controls α. Results are presented by formulation/compound for each
microbial strain tested. NI—no inhibition; NT—not tested.
THEDES/Compound E. coli P. aeruginosa S. aureus MRSA MRSE C. albicans
POH 17.50 ± 0.41 I 20.33 ± 0.47 19.17 ± 0.24 21.50 ± 0.70 31.33 ± 1.70
IBU NI I NI NI NI NI
POH:IBU 4:1 16. 7 ± 0.94 I 1.83 ± 0.24 22.50 ± 0.71 * 24.33 ± 0.85 * 25.60 ± 0.94 *
POH:IBU 6:1 17.33 ± 0.82 I 9.33 ± 0.41 22.33 ± 2.94 * 24.50 ± 1.97 * 30.67 ± 0.81
POH:IBU 8:1 15.33 ± 0.94 I 0.33 ± 0.47 21.00 ± 0.41 20.83 ± 0.24 32.00 ± 1.67
Steril water NI I NI NI NI NI
α Statistical n lysis was performed for all tested THEDES, and the data were considered tatistically different for
p values < 0.05. * Denotes significant differences when compared with the isolated POH.
As can be easily seen by analyzing the obtained inhibition halo measurements, both the isolated
POH and all the tested THEDES display relevant anti icrobial activity against the selected panel of
microorganisms, with the exceptio of . aeruginosa, s o casing the efficacy of these formulations
ag inst not only Gram-positive b t i . albicans, a fungus with a “Gram-positive-like”
membrane structure, but also against r acteria, such as E. coli. Considering th results
obtained in DDA, all the THEDES formulations were selected f r posteri r studies to
determine the MIC/MBC/MFC concentrations for the microorganisms that displayed susceptibility to
the compounds. The results obtained are presented on Tables 3 and 4.
Pharmaceutics 2020, 12, 1121 9 of 17
Table 3. MIC values of the individual counterparts and THEDES. Results are presented by formulation
for each microbial strain tested. ND—not dissolved.
MIC (µg/mL)
Compound/THEDES E. coli S. aureus MRSA MRSE C. albicans
POH 1250 625 625 1250 625
IBU ND ND ND ND ND
POH:IBU 4:1 1250 1250 1250 1250 625
POH:IBU 6:1 1250 1250 1250 1250 625
POH:IBU 8:1 1250 625 625 625 625
Table 4. MBC/MFC values of the individual counterparts and THEDES. Results are presented by
formulation for each microbial strain tested. ND—not dissolved.
MBC/MFC (µg/mL)
Compound/THEDES E. coli S. aureus MRSA MRSE C. albicans
POH 2500 1250 1250 2500 1250
IBU ND ND ND ND ND
POH:IBU 4:1 2500 2500 2500 2500 1250
POH:IBU 6:1 2500 2500 2500 2500 1250
POH:IBU 8:1 2500 1250 1250 1250 1250
The obtained concentration values confirm the previously obtained results, which further highlights
the systems’ efficacy against both bacteria types as well as fungi, with the obtained MIC/MBC/MFC values
being concurrent with the inhibition halo measurements. In order to understand these observations,
the absolute mass composition of each formulation was determined and is presented in Figure 6.
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3.4. THEDES Anticancer Activity
POH chemoprotective and anticancer properties, namely against colorectal cancer, have
been widely described [49]. Anti-inflammatory drugs can play an important role in angiogenesis
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and inflammation processes and, therefore, have an important role in tumor progression [50].
Herein, the anticancer activity of the most promising THEDES was explored combining both
the individual compounds with interesting bioactivities. For this purpose, the eutectic system that
was fully liquid at RT and had the most promising antimicrobial activity, POH:IBU 8:1 and POH:IBU
3:1, the system with the lowest molar ratio liquid at 37 ◦C was considered. Furthermore, the effect of
POH and IBU as a physical mixture (POH + IBU) was also investigated, aiming to explore the contrast
between both components as a eutectic entity and as an aqueous solution. The obtained results are
presented in Table 5 and highlighted in Figure 7.
Table 5. EC50 values for the cytotoxicity and antiproliferative assays, and obtained selectivity index,
for the selected THEDES, individual compounds and physical mixtures. Results were obtained from




Cytotoxicity Assay Antiproliferative Assay
POH 4.86 ± 1.58 1 2.37 ± 0.20 1 2.06
IBU 2.89 ± 0.06 2 2.346 ± 0.09 2 1.23
POH:IBU 3:1 8.46 ± 1.13 1.316 ± 0.07 5.89
POH:IBU 8:1 4.35 ± 0.29 1.37 ± 0.09 2.60
POH + IBU 3:1 - 4.51± 0.26 -
POH + IBU 8:1 - 4.43 ± 0.23 -
1 Reported by Rodrigues et al. [51]. 2 Reported by Pereira et al. [35].
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Figure 7. Comparison of the antiproliferative effect of THEDES and a physical mixture of POH
and IBU. (A) POH:IBU 8:1 and a physical mixture of POH and IBU dissolved in cell culture medium
using the same concentration as in the THEDES; (B) POH:IBU 3:1 and a physical mixture of POH
and IBU dissolved in cell culture medium using the same concentration as in the THEDES. Results
were expressed relatively to the control as the mean ± SD of three independent experiments performed
in triplicate.
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4. Discussion
In this work, new THEDES formulations were produced by combining a non-steroidal
anti-inflammatory drug (i.e., IBU) with POH, which is a penetration enhancer that also has anticancer
properties [52–55]. POH was mixed with IBU at equimolar and imbalanced molar ratios to determine
the formulations that would be subjected to further analysis (Table 1). The simplicity of production
is of paramount importance for the pharmaceutical field as THEDES yields are 100% with no
need for further purification steps [56–58]. The DSC analysis of the systems prepared has shown
that by further increasing the mole fraction of POH, a complete suppression on the melting
point ascribed to IBU was achieved, suggesting the loss of lattice arrangement. The depression
of the melting point is highly dependent on the starting components, molar ratio, lattice energy,
intermolecular interactions and entropy [48,59,60]. Similar data was obtained for the other THEDES
systems, being a plausible reason for the establishment of intermolecular interactions between
the counterparts and the supramolecular arrangement of the counterparts while in THEDES
form [39,42,43]. Overall, the DSC data are in good agreement with the naked-eye observations, being also
aligned with previous data reported in the literature for the THEDES based on limonene:IBU [35].
Furthermore, NMR studies confirmed the successful production of the THEDES. Analyzing
the obtained spectra, it is possible to verify the purity of the isolated compounds, since the spectra
presented in Figure 3 are in accordance with previous reports in the literature [61,62]. Additionally, it is
possible to confirm the accuracy of the molar ratios for the various formulations, as the peak integral
values of the THEDES spectra (Figure 4) vary in accordance to the proportion of the formulation’s
components. In general, it is possible to verify the existence of intermolecular interactions between
the THEDES components.
The solubility of an API is often a limiting factor for its bioavailability, with consequences in
its therapeutic effectiveness [63]. In previous studies, it has been reported that eutectic mixtures are
able to increase an API’s solubility [42,64]. NSAIDs such as ibuprofen present very low solubility
in water (≈21 mg/L) [65], but in combination with menthol as an eutectic mixture experiences an
solubility enhancement of 12.76-fold [57]. In another example, the solubility of ibuprofen combined
with limonene in a molar ratio of 1:4 was enhanced 4.3-fold. When the ratio of limonene increases
to 8, the solubility enhancement is of the order of 5.63, comparing to the pure form of ibuprofen [35].
The results obtained in this work do not follow this enhancement trend since the combination of POH
and IBU as a eutectic mixture does not result in an increase in the API’s solubility when compared
with IBU in the powder form (Figure 5).
The antimicrobial potential of the formulated THEDES was evaluated according to two
methodologies. In the first approach, DDA demonstrates that the obtained results are in accordance
with previous accounts in the literature, as terpenoid-derived compounds have well-documented
antimicrobial activity against Gram-positive bacteria and fungi, with some activity against
the Gram-negative ones although at quite a lower extent [33,66–68]. This phenomenon is usually
attributed to the difference in membrane composition/complexity, as Gram-negative bacteria have
more complex membrane structures, with multiple accounts in the literature reporting the presence of
lipopolysaccharides on the cell wall, which hamper the hydrophobic compounds from reaching the cell
and exerting their effects [69–72]. Regarding the complete lack of inhibition for P. aeruginosa, this is most
likely due to the well-reported terpene bioconversion capabilities of the Pseudomonas genus, which have
been in several accounts regarded as one of the most promising biocatalysts for the obtention of
terpene-derived products [73–75]. As for the complete lack of inhibition observed for IBU, this is most
likely a consequence of the compound’s insolubility in aqueous media and consequent incapability
to properly diffuse from the disk into the agar media. After this assessment, the MIC/MBC/MFC
concentrations for the microorganisms that displayed susceptibility to the compounds were determined.
The widespread effect of THEDES on the microorganisms reflects the primary actuation method of
terpenes and other essential oil components, namely, cell membrane perturbation, which is non-specific
in nature and typically less prone to the development of resistance mechanisms [76,77]. It should
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be noted that, in the conditions established, it was not possible to dissolve IBU. Furthermore, while
this compound is well known for its anti-inflammatory capabilities, some accounts in the literature
do report antibacterial activity against certain microorganisms, such as E. coli and Bacillus subtilis
(MIC = 1025–2500 µg/mL) [78,79]. This slight antibacterial activity verified for other organisms may
explain why even though MRSE shows greater MIC/MBC values for isolated POH than both S. aureus
and MRSA, the values obtained for the formulation POH:IBU 8:1 was the same across all the strains.
This phenomenon may be the consequence of both the added bioavailability of IBU as well as a possible
synergistic effect between the compounds while in THEDES form. This fact has been previously
reported in the literature, where it is stated that a THEDES supramolecular arrangement may result in
synergist effects, which may result in a more pronounced effect or even reduced toxicity [35,80,81].
Nevertheless, considering the absolute mass composition of these formulations (Figure 6), the major
contributor for the verified antimicrobial effect is in all likelihood POH.
Concerning the study on the anticancer activity of the THEDES prepared, the EC50 results obtained
from the cytotoxicity assay for both systems revealed an increase in the cytotoxic profile towards
normal colonic cells (Caco-2 model) as a result of the increase of POH ratio in the eutectic system.
These results suggest that the cytotoxic effect of these THEDES is mainly due to the action of the POH
itself, as it was expected from what has been reported in the literature [49]. This is also verified
when compared to previously reported data on the cytotoxic effect of POH towards this cell line,
since the system with a higher molar ratio of POH has a similar cytotoxic profile as POH itself [51].
Although both systems presented similar anticancer effects, with analogous antiproliferative results
on colorectal cancer cells (HT29), the POH:IBU (3:1) was the most proficient system to inhibit HT29
proliferation without compromising normal cell viability. This effect may be due to the selective action
of the eutectic system on the cancer cell membrane, which induces perturbation and ultimately its
disruption, as has been reported for several other DES [82,83]. To better understand the uniqueness of
these eutectic entities, the antiproliferative activity of a simple physical mixture of the components
was evaluated. Interestingly, the antiproliferative activity revealed to be completely different from
both eutectic formulations (Figure 7A,B). These results give the indication that the supramolecular
rearrangement promoted by the eutectic formulation allows the preparation of tailor-made systems
towards colorectal cancer cells. The selectivity index (SI) of a compound is a parameter used to
express a compound’s in vitro efficacy in the inhibition of a particular target. For this matter, it is
the result of the ratio between the antiproliferative effect and the cytotoxicity of the eutectic system.
Thus, from the SI results we are able to have a preliminary representation of the anticancer potential of
the THEDES, alongside with their safety, thereby illustrating a possible therapeutic window for these
systems. Therefore, although both systems presented interesting results for the antiproliferative assay,
a POH:IBU of 3:1 seems to be the most promising for further establishment of its anticancer activity.
5. Conclusions
Herein, POH was for the first time successfully combined with IBU and yielded a THEDES
liquid sample when mixed in adequate molar ratios. The obtained data showed that the properties of
the parent species do not suffer any negative effects due to their inclusion in a DES supramolecular
effect, retaining, generally, the antimicrobial and anticancer proprieties of its major component, POH.
In fact, the results obtained in this study point to the existence of synergistic/additive effects resulting
from the DES interaction between POH and IBU. The remarkable properties of these THEDES systems
mainly lie in the intermolecular interactions between the components, which allow to tailor their
properties depending on the molar ratio of the two components present in the system (POH:IBU).
The use of THEDES for commercial purposes is still in its infancy; thereby, it is essential to fully
characterize them in terms of their physicochemical and biological properties. This is of extreme
importance to validate the use of THEDES as therapeutic agents. In this work, the use of THEDES based
on POH:IBU has shown to have great potential, both as antimicrobial agent and as anticancer agent.
Interestingly, the therapeutic properties of the THEDES designed here are dependent on the molar
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ratio used, which may lead to selective applications of POH:IBU. The attractive properties displayed
by these formulations encourage further studies to understand the detailed mechanisms of action of
these systems for the envisioned purposes, namely, infection prevention/treatment and applications in
cancer therapy.
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